Start Time: 08:00 January 1, 0000 9:02 AM ET Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2021 Earnings Conference Call March 01, 2022, 08:00 AM ET Company Participants David Meeker - Chairman, President and CEO Linda Shapiro - CMO Hunter Smith - CFO Yann Mazabraud - EVP, Head of International Jennifer Chien - EVP, Head of North America David Connolly - Head of IR and Corporate Communications Conference Call Participants Phil Nadeau - Cowen and Company Joseph Stringer - Needham & Company Michael Higgins - ...

Rhythm Pharmaceuticals Fourth Quarter / Year End 2021 Financial Results March 1, 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements 2 This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without limitations statements regarding the potential, safety, efficacy, ...

Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity November 2021 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2021 Earnings Conference Call November 2, 2021 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & Chief Executive Officer Linda Shapiro - Chief Medical Officer Jennifer Chien - Executive Vice President, Head of North America Hunter Smith - Chief Financial Officer Conference Call Participants Phil Nadeau - Cowen and Co. Joseph Stringer - Needham & Company Corinne Jenkins - Go ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2021 Results Earnings Conference Call August 3, 2021 8:00 AM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Murray Stewart - Chief Medical Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Phil Nad ...

Rhythm Pharmaceuticals Second Quarter 2021 Financial Results August 3, 2021 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Agenda for Today's Call David Meeker, MD, Chair, President and Chief Executive: Overview Murray Stewart, MD, Chief Medical Officer: Clinical and Regulatory Update Jennifer Chien, EVP, Head of North America: U.S. Commercial Update Yann Mazabraud, EVP, Head of International: International Update Hunter Smith, Chief Financial Officer: 2Q 2021 Financial Results Q&A ® 2 Forward Looki ...

Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity May 2021 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements 2 This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without limitations statement ...

Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic disorders of obesity August 2020 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without limitations sta ...

Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic disorders of obesity June 2020 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements regarding Rhyt ...